why choose us

First received: September 02, 2022

Clinical Trial: BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Study Status: Completed

Recruit Status: RECRUITING

Condition: Metastatic Pancreatic Ductal Adenocarcinoma

Study Type: INTERVENTIONAL


Official Title: Phase II Trial of BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Brief Summary: Single-arm, open label study to determine the 18 week progression-free survival rate of the combination of BXCL701 and pembrolizumab in patients with pancreatic ductal adenocarcinoma in the second-line metastatic setting.

Read more